vTv Therapeutics (VTVT) Current Deferred Revenue (2015 - 2026)

vTv Therapeutics has disclosed Current Deferred Revenue across 12 years of filings, most recently posting $1.3 million for Q2 2026.

• In Q2 2026, Current Deferred Revenue changed N/A year-over-year to $1.3 million; the TTM figure through Jun 2026 stood at $1.3 million (changed N/A YoY), while the FY2025 annual figure was $18.7 million, changed 0.17% from the prior year.
• Current Deferred Revenue came in at $1.3 million for Q2 2026 at vTv Therapeutics, roughly flat from $1.3 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $18.7 million in Q4 2025 to a low of $17000.0 in Q4 2022.
• Average Current Deferred Revenue over 5 years is $10.1 million, with a median of $18.7 million recorded in 2024.
• Year-over-year, Current Deferred Revenue jumped 109817.65% in 2023 and tumbled 99.91% in 2024.
• Over 5 years, Current Deferred Revenue stood at $17000.0 in 2022, then jumped by 109817.65% to $18.7 million in 2023, then dropped by 0.09% to $18.7 million in 2024, then advanced by 0.17% to $18.7 million in 2025, then sank by 93.05% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $1.3 million in Q2 2026, $1.3 million in Q1 2026, and $18.7 million in Q4 2025.